The U.S. Court of Appeals for the Federal Circuit has denied attorney fees to a medical device manufacturer in a dispute relating to an expandable surgical reamer patent, ruling that the district court did not abuse its discretion in denying the prevailing defendant’s motion for attorney fees. The district court rejected the plaintiff’s proposed claim…
Applying the so-called ‘Actavis Questions’ (further to the Supreme Court decision in Actavis v Eli Lilly), the Court of Appeal reached a different conclusion from the Patents Court on the issue of infringement. However, as the Court of Appeal upheld the first instance Court’s decision that the patent was invalid, this ultimately did not change…
The Barcelona patent courts have provided further guidance on preliminary injunctions within the context of trade fairs, where the standard of evidence is higher than usual. Indirect evidence, such as an expert report based on a video of the competitor’s allegedly infringing machine, is generally not good enough. If the patentee lacks direct, “hands-on” evidence…
The judgment addresses the question of the scope of the co-inventors’ right to obtain a patent, prior to the grant of the patent. The Supreme Court presented the view that the substance of the co-inventors’ right to a patent allows them to use the invention in an unlimited way and, consequently, obliges them to settle…
In light of the Teva/Gilead-judgment handed down on 25 July 2018 by the CJEU (C-121/17) as well as the latest referral from the German Federal Patent Court dated 17 October 2017 in re Sitagliptin III (14 W (pat) 12/17), which is pending as C-650/17, Prof. Meier-Beck, the presiding Judge of the German Federal Supreme Court,…
The U.S. Court of Appeals for the Federal Circuit has affirmed a $139.8 million jury verdict in favor of Sprint Communications against Time Warner for infringement of five Sprint patents related to VoIP technology. The appeals court concluded that the district properly admitted evidence relating to the jury verdict in an earlier, related case brought…
The Court of Appeal overturned the Patent Court’s first instance decision concerning the validity of one of ICOS’s patents (licensed to Eli Lilly) covering a 1 to 5mg dosage form of tadalafil (Cialis®) for oral administration up to a maximum of 5mg per day for the treatment of sexual dysfunction. The Court held that the…
The FCJ confirmed that a new means of challenge based on the technical content of a document filed for the first time in the course of appeal proceedings is only to be admitted under the provisions of Section 531 paragraph 2 numbers 1 to 3 of the German Code of Civil Procedure, irrespective of whether…
A quarter-century after supplementary protection certificates (SPCs) were introduced in the European Union, there are still a number of unresolved questions as to which types of products are, in principle, eligible for SPC protection. One further important piece in this puzzle will be provided by the CJEU’s forthcoming decision in the pending referral Abraxis Bioscience…
In a Judgment dated 26 July 2018, the influential Barcelona Court of Appeal (Section 15) rejected an overly narrow, “literalistic” interpretation of a patent claim. A claim’s terms must be interpreted according to the meaning that a person skilled in the art would give them – even if it is not the most scientifically “puristic”…
